Valeant plans to enhance buyout bid for Allergan

05/14/2014 | MedicalXpress.com

Valeant Pharmaceuticals said it planned to improve its nearly $46 billion takeover offer for U.S. firm Allergan to show its commitment to completing the deal, just a day after the latter formally rejected its unsolicited bid. "We are prepared to pay a full and fair price, but consistent with our track record, we will remain financially disciplined," said Valeant Chairman and CEO Michael Pearson in a letter to Allergan shareholders.

View Full Article in:

MedicalXpress.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD